Newspaper cutting with regard to publication of audited financial results for the quarter / year ended on March 31, 2026, in Financial Express on May 20, 2026.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences has published its audited financial results for Q4 FY2026 and full year ended March 31, 2026. For Q4, total income from operations was Rs 75,870 million, up 16.3% from Rs 65,279 million in Q4 FY2025. Net profit after tax (post non-controlling interest) stood at Rs 12,725 million vs Rs 11,709 million in Q4 FY2025, an increase of 8.7%. For the full year FY2026, total income was Rs 2,71,484 million versus Rs 2,32,415 million in FY2025, showing strong 16.8% revenue growth. Full year net profit after tax increased to Rs 50,400 million from Rs 45,255 million, up 11.4% YoY. EPS for FY2026 was Rs 50.09 compared to Rs 44.97 in FY2025. The results were approved by the Board on May 19, 2026.
Zydus Lifesciences delivered solid double-digit revenue and profit growth for both Q4 and full year FY2026, with strong margins maintained. The consistent performance across quarters signals operational stability, which is positive for shareholders and could support the stock price.